Flatiron Health is presenting five abstracts at this year’s #ISPOREurope that leverage our high-quality, multinational oncology data assets and novel methodological approaches, unlocking critical evidence to accelerate access to cancer treatments worldwide. Check out what Flatiron experts will be onsite and schedule time with them to learn more: https://lnkd.in/eSXMzi8X

ANNOUNCED TODAY: Flatiron Health to present seven abstracts at #ASH24. Through our research accepted at this year’s conference, Flatiron’s scientists and collaborators are using our #RWD at scale to improve our understanding of current therapies & identify treatment gaps for patients with hematologic malignancies. Learn more: http://spkl.io/6044fpLfI

With 230,000 new cases of lung cancer a year in the United States, it remains one of the most active areas of #cancerresearch today. This #LungCancerAwarenessMonth, we’re highlighting one of Flatiron Health’s #1000Publications which used #RWD to define timelines for progression-free NSCLC patients to discontinue immunotherapy treatments after two years without compromising survival benefits. Using #RWD, this research has the potential for direct impact on the quality of life for patients with NSCLC. If you’re interested in reading the full study, click here: http://spkl.io/6045fplaP

Flatiron’s Neal Meropol spoke on an insightful panel at the Friends of Cancer Research Annual Meeting earlier today building off a recently published white paper. The conversation revealed a few key insights, including: 🌟 Incorporating pragmatic elements into #clinicaltrial designs can enhance generalizability and efficiency 🔍 Opportunities for pragmatic trial elements exist broadly, however, identifying appropriate pragmatic elements based on the research question, trial objectives, and clinical setting is critical 💾 Tech like #AI-enabled trial matching, EHR-to-EDC connectors, and more are viable pragmatic elements that can lower the burden and reduce the complexity of clinical trials Read the full white paper to learn more: http://spkl.io/6046fpWaA

ANNOUNCED TODAY: Flatiron Health is integrating Tempus AI’s comprehensive genomic testing into OncoEMR®, providing for the 4,200+ providers across the Flatiron network with access to Tempus’ suite of testing options and enhancing their ability to deliver personalized cancer care. Learn more about how this initiative will expand possibilities at the point of care: http://spkl.io/6049fpjy1

We're driven by a purpose: to improve and extend lives by learning from every person with cancer. Our Life Sciences Hub in #RaleighDurham is growing, and we're looking for problem solvers with integrity at their core. Make a difference in cancer care—apply today: https://shorturl.at/LeL8B

Flatiron FORUM, a consortium of multiple biopharma and life science companies that work closely with Flatiron, have recently demonstrated opportunities to close evidence gaps and address transportability research needs globally on a series of pre-competitive studies. Read a recent blog by Flatiron’s Blythe Adamson, PhD, MPH for more on the potential of Flatiron’s EHR-derived data from the UK, Germany, and Japan, on-going projects, and future directions to expand multi-national data capabilities and refine our methodologies that will play a pivotal role in shaping the future of oncology and global health policy. Heading to #ISPOREurope? Reach out to our team of experts today to connect on this and more onsite: https://lnkd.in/eSXMzi8X

ANNOUNCED TODAY: Flatiron Health to present five abstracts at this year’s #ISPOREurope. Flatiron’s research accepted for presentation at this year’s conference leverages our high-quality, multinational oncology data assets and novel methodological approaches to shape ways international oncology #realworlddata can address complex healthcare regulatory decision-making worldwide. Learn more: http://spkl.io/6043fTnNb

We are proud to once again partner with more than 2,000 companies to ensure our employees across the country have #TimeToVote on Election Day, as we recognize today’s General Election as an annual U.S. holiday where employees can exercise their civic duty and vote. #TimetoVote is a nonpartisan, business-led initiative to help ensure employees across America don’t have to choose between voting and earning a paycheck. To learn more about or join the #TimetoVote movement, visit MakeTimeToVote.org

Precision oncology, fueled by advances in biomarker testing and linked #RWD, is transforming patient care. Flatiron’s Kristi M. Zimmerman Savill, PhD shares her perspective on how advances in #molecularprofiling tech and linked real-world clinico-omics data are shepherding a new era of precision oncology research in a recent article. Interested in learning more about the power of RWD and molecular profiling technology? Join us on November 8th at the SITC Annual Meeting for our Symposium: A New Era of Precision Immuno-Oncology Research Fueled by Omics-Based Technology, Testing, and Linked Real-World Data https://lnkd.in/eDqyatKF